Nanoform Finland Oyj Share Price Nasdaq Helsinki
Equities
FI4000330972
Biotechnology & Medical Research
Sales 2024 * | 7.48M 7.99M 640M | Sales 2025 * | 14.6M 15.59M 1.25B | Capitalization | 184M 196M 15.71B |
---|---|---|---|---|---|
Net income 2024 * | -15M -16.02M -1.28B | Net income 2025 * | -11M -11.74M -941M | EV / Sales 2024 * | 20.4 x |
Net cash position 2024 * | 31M 33.1M 2.65B | Net cash position 2025 * | 21.34M 22.78M 1.82B | EV / Sales 2025 * | 11.1 x |
P/E ratio 2024 * |
-11
x | P/E ratio 2025 * |
-15.4
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 61.6% |
Latest transcript on Nanoform Finland Oyj
Managers | Title | Age | Since |
---|---|---|---|
Edward Hæggström
CEO | Chief Executive Officer | 55 | 31/12/14 |
Albert Häggström
DFI | Director of Finance/CFO | 53 | 31/12/14 |
Investor Relations Contact | - | 30/04/19 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 68 | 01/04/19 | |
Mads Laustsen
BRD | Director/Board Member | 67 | 31/12/18 |
Albert Häggström
DFI | Director of Finance/CFO | 53 | 31/12/14 |
1st Jan change | Capi. | |
---|---|---|
+0.17% | 42.19B | |
+10.92% | 42.24B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+5.23% | 24.63B | |
-24.79% | 18.2B | |
+26.69% | 12.01B | |
-3.13% | 11.76B | |
+6.57% | 10.4B |